| Mr Michael E Ferrante, CAA | |
|
10 Hospital Dr, Saint Peters, MO 63376-1659 | |
| (314) 895-3828 | |
| (314) 895-3827 |
| Full Name | Mr Michael E Ferrante |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology Assistant |
| Experience | 11 Years |
| Location | 10 Hospital Dr, Saint Peters, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952745101 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Indiana University Health | Indianapolis, IN | Hospital |
| Indiana University Health North Hospital | Carmel, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Iu Anesthesiology Associates, Llc | 5395730303 | 148 |
| Indiana University Health Care Associates Inc | 5799755864 | 882 |
News Archive
3M Drug Delivery Systems has signed an agreement with VaxInnate Corporation under which VaxInnate acquires the use of 3M's patented toll-like receptor (TLR) agonists for use as vaccine adjuvants. Data suggest that 3M's TLR agonists could enhance vaccine potency, potentially enabling VaxInnate to develop vaccines that provide faster, more robust protection.
In a first-of-its-kind look at human kidney development, researchers at The Saban Research Institute of Children's Hospital Los Angeles have isolated human nephron progenitor (NP) cells.
Celgene International Sàrl announced that data evaluating combination therapy REVLIMID (lenalidomide) and dexamethasone in patients with high-risk smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting in New Orleans, LA. The landmark study demonstrated REVLIMID and dexamethasone prolonged time to progression, including complete responses, with manageable toxicity.
Virginia Life Science Investments, LLC and other investors have completed a recapitalization and management restructuring of Cupron, Inc., a Delaware corporation established in 2001, with principal offices in Modi'in, Israel. The transaction provides significant new capital to support the continued growth and development of Cupron Inc.; as well as the formation and initial capitalization of an independent new entity, Cupron Medical Inc., a Delaware corporation with principal offices in Richmond, VA.
› Verified 7 days ago
| Entity Name | Iu Anesthesiology Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285684407 PECOS PAC ID: 5395730303 Enrollment ID: O20040419001228 |
News Archive
3M Drug Delivery Systems has signed an agreement with VaxInnate Corporation under which VaxInnate acquires the use of 3M's patented toll-like receptor (TLR) agonists for use as vaccine adjuvants. Data suggest that 3M's TLR agonists could enhance vaccine potency, potentially enabling VaxInnate to develop vaccines that provide faster, more robust protection.
In a first-of-its-kind look at human kidney development, researchers at The Saban Research Institute of Children's Hospital Los Angeles have isolated human nephron progenitor (NP) cells.
Celgene International Sàrl announced that data evaluating combination therapy REVLIMID (lenalidomide) and dexamethasone in patients with high-risk smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting in New Orleans, LA. The landmark study demonstrated REVLIMID and dexamethasone prolonged time to progression, including complete responses, with manageable toxicity.
Virginia Life Science Investments, LLC and other investors have completed a recapitalization and management restructuring of Cupron, Inc., a Delaware corporation established in 2001, with principal offices in Modi'in, Israel. The transaction provides significant new capital to support the continued growth and development of Cupron Inc.; as well as the formation and initial capitalization of an independent new entity, Cupron Medical Inc., a Delaware corporation with principal offices in Richmond, VA.
› Verified 7 days ago
| Entity Name | Indiana University Health Care Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902032832 PECOS PAC ID: 5799755864 Enrollment ID: O20040727000955 |
News Archive
3M Drug Delivery Systems has signed an agreement with VaxInnate Corporation under which VaxInnate acquires the use of 3M's patented toll-like receptor (TLR) agonists for use as vaccine adjuvants. Data suggest that 3M's TLR agonists could enhance vaccine potency, potentially enabling VaxInnate to develop vaccines that provide faster, more robust protection.
In a first-of-its-kind look at human kidney development, researchers at The Saban Research Institute of Children's Hospital Los Angeles have isolated human nephron progenitor (NP) cells.
Celgene International Sàrl announced that data evaluating combination therapy REVLIMID (lenalidomide) and dexamethasone in patients with high-risk smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting in New Orleans, LA. The landmark study demonstrated REVLIMID and dexamethasone prolonged time to progression, including complete responses, with manageable toxicity.
Virginia Life Science Investments, LLC and other investors have completed a recapitalization and management restructuring of Cupron, Inc., a Delaware corporation established in 2001, with principal offices in Modi'in, Israel. The transaction provides significant new capital to support the continued growth and development of Cupron Inc.; as well as the formation and initial capitalization of an independent new entity, Cupron Medical Inc., a Delaware corporation with principal offices in Richmond, VA.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Michael E Ferrante, CAA 250 N Shadeland Ave, Indianapolis, IN 46219-4959 Ph: () - | Mr Michael E Ferrante, CAA 10 Hospital Dr, Saint Peters, MO 63376-1659 Ph: (314) 895-3828 |
News Archive
3M Drug Delivery Systems has signed an agreement with VaxInnate Corporation under which VaxInnate acquires the use of 3M's patented toll-like receptor (TLR) agonists for use as vaccine adjuvants. Data suggest that 3M's TLR agonists could enhance vaccine potency, potentially enabling VaxInnate to develop vaccines that provide faster, more robust protection.
In a first-of-its-kind look at human kidney development, researchers at The Saban Research Institute of Children's Hospital Los Angeles have isolated human nephron progenitor (NP) cells.
Celgene International Sàrl announced that data evaluating combination therapy REVLIMID (lenalidomide) and dexamethasone in patients with high-risk smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting in New Orleans, LA. The landmark study demonstrated REVLIMID and dexamethasone prolonged time to progression, including complete responses, with manageable toxicity.
Virginia Life Science Investments, LLC and other investors have completed a recapitalization and management restructuring of Cupron, Inc., a Delaware corporation established in 2001, with principal offices in Modi'in, Israel. The transaction provides significant new capital to support the continued growth and development of Cupron Inc.; as well as the formation and initial capitalization of an independent new entity, Cupron Medical Inc., a Delaware corporation with principal offices in Richmond, VA.
› Verified 7 days ago
Rebecca Christine Hoffman, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 10 Hospital Dr, Saint Peters, MO 63376 Phone: 314-895-3828 Fax: 314-895-3827 | |
Patricia Sue Kipper, AA-C Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 10 Hospital Dr, Saint Peters, MO 63376 Phone: 314-895-3828 Fax: 314-895-3827 |